RSV vaccine safety findings reported one year after recommendation for adults 60 and olderEarly safety monitoring of RSV vaccines for older adults shows no major concerns

This report describes safety findings from the first year after the respiratory syncytial virus (RSV) vaccine was recommended for adults aged 60 years and older in the United States. The study type, phase, and publication format were not reported. The population consisted of persons in this age group who received an RSV vaccine, but the sample size was not provided. No comparator group was specified for the analysis.

No main results on vaccine safety or efficacy were reported in the provided data. The assessment did not report on the incidence of adverse events, serious adverse events, discontinuations due to side effects, or general tolerability. The follow-up period covered approximately one year post-recommendation.

Key limitations include the absence of reported results, which prevents any assessment of the safety signal profile. The lack of a comparator group and unreported sample size further constrain interpretation. The funding sources and potential conflicts of interest were also not reported. For clinical practice, this report indicates that safety monitoring is ongoing, but the current evidence summary does not provide specific data to inform risk-benefit discussions for individual patients.